Infectious Disease Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers

This Phase 3 trial is testing a new dengue vaccine in infants and toddlers to see if it is safe and produces a strong immune response. The vaccine is given in two doses, three months apart, to help protect young children from dengue fever, a mosquito-borne illness common in tropical regions. Recruiting is ongoing in Colombia and Thailand, and if the vaccine proves effective, it could offer a valuable tool to reduce dengue infections in young children.

The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E

In this completed Phase 3 study, researchers tested an oral rotavirus vaccine in over 4,000 healthy infants in Chile to see how well it prevents rotavirus gastroenteritis. Rotavirus is a leading cause of severe diarrhea in infants, which can lead to hospitalization. The vaccine was given in three doses, and the results will provide important information to help improve protection for infants against this common and sometimes serious illness.

Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years

This ongoing Phase 3b trial is evaluating a human papillomavirus (HPV) vaccine in young women living with HIV across multiple African countries. HPV infection can increase the risk of cervical cancer, especially in people with weakened immune systems. By testing safety and immune response with two- and three-dose schedules, this study aims to provide better protection against HPV and related cancers for this high-risk group.

Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

This completed Phase 3 study looked at a hexavalent vaccine that protects children against six diseases, including diphtheria, tetanus, pertussis, hepatitis B, Hib, and polio. By reducing the dose of one component (IPV), the vaccine could become more affordable and easier to distribute, especially in low-resource settings. The study involved over 1,500 children in India and Bangladesh, and its findings could help expand vaccine access globally.

A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants

This Phase 3 trial tested a vaccine designed to protect infants from respiratory syncytial virus (RSV) by vaccinating pregnant women living with HIV. RSV can cause severe lung infections in young babies, particularly those born to mothers with HIV. The study, conducted in South Africa with 681 participants, has completed and its results will help determine if this approach can safely boost infant immunity against RSV.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.